Literature DB >> 34089462

HIT in the head: a systematic review of cerebral venous sinus thrombosis in classical and autoimmune heparin-induced thrombocytopenia.

Megan M J Bauman1,2, Ryan M Naylor1, Eelco F Wijdicks3.   

Abstract

Heparin-induced thrombocytopenia (HIT) causes thrombosis and thrombocytopenia, usually due to prior heparin exposure, so-called classical HIT. However, in the autoimmune form, the signs and symptoms of HIT occur without prior heparin exposure. Development of cerebral venous sinus thrombosis (CVST) secondary to HIT is a rare occurrence, with relatively few reports in the literature. There is a need to better understand the clinical presentation and treatment paradigms in these rare cases. Therefore, we present the first systematic review of CVST occurring in classical and autoimmune HIT. Cases of HIT-induced CVST were identified through a systematic search of Pubmed from the date of inception to March 2021. Literature search revealed 21 cases of HIT and associated CVST with six cases (28.6%) of autoimmune HIT. Patients presented with signs and symptoms consistent with increased intracranial pressure, intracerebral hemorrhage (ICH), and/or focal neurologic deficits. Headache was the most common symptom with 12 patients (60.0%) presenting as such. 10 patients (47.6%) included in the study developed ICH. Non-heparin anticoagulants, especially direct thrombin inhibitors, were the first-line treatment for the majority of patients (55.6%). Intravenous immunoglobulin (IVIG) was used as treatment for select patients (16.7%) with autoimmune HIT. Few patients received surgical intervention for CVST (14.3%) or ICH (30.0%). Four patients had a full recovery, four patients had residual deficits, and seven patients ultimately expired. Symptoms of HIT-induced CVST are often related to CNS dysfunction. Non-heparin anticoagulants are important to treat CVST, even when patients have concomitant ICH, and may be supplemented with IVIG if treating autoimmune HIT. Rapid identification and treatment of HIT-induced CVST is imperative in order to prevent morbidity and mortality.
© 2021. The Author(s), under exclusive licence to Springer Science+Business Media, LLC, part of Springer Nature.

Entities:  

Keywords:  Cerebral venous sinus thrombosis; Heparin-induced thrombocytopenia; Intracranial hemorrhage; Neurocritical care; Stroke

Mesh:

Substances:

Year:  2021        PMID: 34089462     DOI: 10.1007/s11239-021-02484-6

Source DB:  PubMed          Journal:  J Thromb Thrombolysis        ISSN: 0929-5305            Impact factor:   2.300


  28 in total

1.  Temporal aspects of heparin-induced thrombocytopenia.

Authors:  T E Warkentin; J G Kelton
Journal:  N Engl J Med       Date:  2001-04-26       Impact factor: 91.245

2.  Fatal cerebral venous sinus thrombosis in heparin-induced thrombotic thrombocytopenia.

Authors:  A Meýer-Lindenberg; E M Quenzel; E Bierhoff; H Wolff; E Schindler; R Biniek
Journal:  Eur Neurol       Date:  1997       Impact factor: 1.710

3.  Cerebral venous thrombosis due to heparin-induced thrombocytopenia.

Authors:  A P Kyritsis; E C Williams; H S Schutta
Journal:  Stroke       Date:  1990-10       Impact factor: 7.914

4.  Spontaneous heparin-induced thrombocytopenia syndrome without any proximate heparin exposure, infection, or inflammatory condition: Atypical clinical features with heparin-dependent platelet activating antibodies.

Authors:  Takuya Okata; Shigeki Miyata; Fumio Miyashita; Takuma Maeda; Kazunori Toyoda
Journal:  Platelets       Date:  2014-11-10       Impact factor: 3.862

5.  Delayed-onset heparin-induced thrombocytopenia and thrombosis.

Authors:  T E Warkentin; J G Kelton
Journal:  Ann Intern Med       Date:  2001-10-02       Impact factor: 25.391

6.  Cerebral Venous Sinus Thrombosis Due to Low-molecular-weight Heparin-induced Thrombocytopenia.

Authors:  Ezequiel Gleichgerrcht; Ming Y Lim; Tanya N Turan
Journal:  Neurologist       Date:  2017-11       Impact factor: 1.398

7.  Autoimmune heparin-induced thrombocytopenia of delayed onset: a clinical challenge.

Authors:  Anne Kuitunen; Marjatta Sinisalo; Annukka Vahtera; Leena Hiltunen; Kaija Javela; Outi Laine
Journal:  Transfusion       Date:  2018-10-04       Impact factor: 3.157

Review 8.  Heparin-induced thrombocytopenia and cerebral venous sinus thrombosis: case report and literature review.

Authors:  Mark J Fesler; Michael H Creer; John M Richart; Randall Edgell; Necat Havlioglu; Gershom Norfleet; Salvador Cruz-Flores
Journal:  Neurocrit Care       Date:  2011-08       Impact factor: 3.210

9.  Unilateral venous thalamic infarction in a child mimicking a thalamic tumor.

Authors:  Verena Haug; Michaela Linder-Lucht; Barbara Zieger; Rudolf Korinthenberg; Volker Mall; Irina Mader
Journal:  J Child Neurol       Date:  2009-01       Impact factor: 1.987

10.  Cerebral venous sinus thrombosis associated with spontaneous heparin-induced thrombocytopenia syndrome after total knee arthroplasty.

Authors:  Steven R Hwang; Yuxiang Wang; Erika L Weil; Anand Padmanabhan; Theodore E Warkentin; Rajiv K Pruthi
Journal:  Platelets       Date:  2020-10-01       Impact factor: 3.862

View more
  5 in total

Review 1.  Early recognition and treatment of pre-VITT syndrome after adenoviral vector-based SARS-CoV-2 vaccination may prevent from thrombotic complications: review of published cases and clinical pathway.

Authors:  Farid Salih; Siegfried Kohler; Linda Schönborn; Thomas Thiele; Andreas Greinacher; Matthias Endres
Journal:  Eur Heart J Open       Date:  2022-05-16

2.  A Rare Case of Extensive Cerebral Venous Sinus Thrombosis Complicated by Heparin-Induced Thrombocytopenia.

Authors:  Noman Ahmed Jang Khan; Ashar Farooqi; Mohamed Alsharedi
Journal:  Case Rep Hematol       Date:  2022-06-06

3.  Thrombosis with Thrombocytopenia Syndrome After Administration of AZD1222 or Ad26.COV2.S Vaccine for COVID-19: A Systematic Review.

Authors:  Usama Waqar; Shaheer Ahmed; Syed M H Ali Gardezi; Muhammad Sarmad Tahir; Zain Ul Abidin; Ali Hussain; Natasha Ali; Syed Faisal Mahmood
Journal:  Clin Appl Thromb Hemost       Date:  2021 Jan-Dec       Impact factor: 2.389

4.  Time to consider neuroinflammation as a booster effect of cerebral venous sinus thrombosis in vaccine-induced immune thrombotic thrombocytopenia?

Authors:  Benjamin Marchandot; Adrien Carmona; Olivier Morel
Journal:  J Thromb Thrombolysis       Date:  2021-11-09       Impact factor: 5.221

5.  Spontaneous Reporting to Regulatory Authorities of Suspected Adverse Drug Reactions to COVID-19 Vaccines Over Time: The Effect of Publicity.

Authors:  Robin E Ferner; Richard J Stevens; Christopher Anton; Jeffrey K Aronson
Journal:  Drug Saf       Date:  2022-01-22       Impact factor: 5.228

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.